1 / 6

Europe Pneumococcal Vaccine Market

Europe Pneumococcal Vaccine Market

Nilam5
Download Presentation

Europe Pneumococcal Vaccine Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Europe Pneumococcal Vaccine Market Europe Pneumococcal Vaccine Market Size Worth USD 2.9 Billion By 2032 | CAGR: 5.7% The Europe pneumococcal vaccine market size was valued at USD 1.8 billion in 2023. The market is anticipated to grow from USD 1.9 billion in 2024 to USD 2.9 billion by 2032, exhibiting a CAGR of 5.7% during 2024–2032.

  2. Europe Pneumococcal Vaccine Market • The Europe pneumococcal vaccine market size was valued at USD 1.8 billion in 2023. The market is anticipated to grow from USD 1.9 billion in 2024 to USD 2.9 billion by 2032, exhibiting a CAGR of 5.7% during 2024–2032. Request To Sample: https://www.polarismarketresearch.com/industry-analysis/europe-pneumococcal-vaccine-market/request-for-sample

  3. Europe Pneumococcal Vaccine Market Key Market Players : • Astellas Pharma Inc • CSL Ltd • GSK plc • Merck & Co. Inc • Panacea Biotech Ltd • GPN Vaccines • SK Bioscience • Pfizer Inc. • Sanofi S.A • Serum Life Sciences Ltd • Talley Group Ltd • Walvax Biotechnology Co. Ltd

  4. Europe Pneumococcal Vaccine Market Europe Pneumococcal Vaccine Market Report Highlights • Based on type, the pneumococcal conjugate vaccines segment dominated the Europe pneumococcal vaccine market in 2023 due to their effectiveness in preventing a broader range of pneumococcal diseases and advances in vaccine technology. • In terms of end users, the public sector segment accounted for a larger market share in 2023, owing to the rising funding from international health organizations. • The UK dominated the market in Europe in 2023, owing to a well-established immunization program, a growing elderly population, and ongoing research and advancements in vaccine technology. • The market in Germany is projected to register the fastest growth during the forecast period, attributable to the robust healthcare system and the growing awareness of the importance of vaccinations, particularly among healthcare professionals and the general public.

  5. 𝐀𝐛𝐨𝐮𝐭 𝐔𝐬: Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defence, among different ventures present globally. 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗜𝗻𝗳𝗼:Polaris Market ResearchPhone: +1-929-297-9727Email: sales@polarismarketresearch.com

More Related